Ultragenyx Analyst Day Presentation slide image

Ultragenyx Analyst Day Presentation

Product approvals since IPO exceed other successful, rare disease companies ultragenyx BioMarin Genzyme Years from IPO to 1st approval^ # of approvals^ 10y post-IPO # of approvals^ 15y post-IPO 8-12* 3 53 2 2 5320 45 Alexion 11 Alnylam 14 0 Vertex 21 0 + Confidential and Proprietary 0 ^Approvals for rare disease indications * Expected based on current pipeline ultragenyx
View entire presentation